About: The COVID 19 novel coronavirus pandemic 2020: seaweeds to the rescue? Why does substantial, supporting research about the antiviral properties of seaweed polysaccharides seem to go unrecognized by the pharmaceutical community in these desperate times?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The COVID 19 novel coronavirus pandemic 2020: seaweeds to the rescue? Why does substantial, supporting research about the antiviral properties of seaweed polysaccharides seem to go unrecognized by the pharmaceutical community in these desperate times? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The COVID 19 novel coronavirus pandemic 2020: seaweeds to the rescue? Why does substantial, supporting research about the antiviral properties of seaweed polysaccharides seem to go unrecognized by the pharmaceutical community in these desperate times?
Creator	Critchley, Alan Pereira, Leonel
Source	Medline; PMC
abstract	Presently, there is lack of a vaccine that would lead to immunization against the virus COVID-19, but here are some of the characteristics that various seaweeds have and which may provide a glimpse into potential solutions of this global health problem in the near future and possibly forearm us for any future such pandemics. Many species of marine algae contain significant quantities of complex structural sulphated polysaccharides that have been shown to inhibit the replication of enveloped viruses. Other compounds, both of red algae (e.g., the lectin griffithsin and the phycocolloid carrageenan), and other sulphated polysaccharides extracted from green algae (i.e., ulvans) and brown algae (i.e., fucoidans) could be potential antiviral therapeutic agents against SARS-CoV-2.
has issue date	2020-06-01(xsd:dateTime)
bibo:doi	10.1007/s10811-020-02143-y
bibo:pmid	32836796
has license	no-cc
sha1sum (hex)	6f25d2706a7d4ae7d2c81f0c5ece56f1db5593cb
schema:url	https://doi.org/10.1007/s10811-020-02143-y
resource representing a document's title	The COVID 19 novel coronavirus pandemic 2020: seaweeds to the rescue? Why does substantial, supporting research about the antiviral properties of seaweed polysaccharides seem to go unrecognized by the pharmaceutical community in these desperate times?
has PubMed Central identifier	PMC7263178
has PubMed identifier	32836796
schema:publication	J Appl Phycol
resource representing a document's body	covid:6f25d2706a7d4ae7d2c81f0c5ece56f1db5593cb#body_text
is schema:about of	named entity 'solutions' named entity 'provide' named entity 'pharmaceutical' named entity 'Other' named entity 'species' named entity 'red algae' named entity 'antiviral' named entity 'vaccine' named entity 'immunization' named entity 'sulphated' named entity 'pharmaceutical' named entity 'seaweed' named entity 'desperate times' named entity 'coronavirus pandemic' named entity 'seaweeds' named entity 'Japan' named entity 'synergistically' named entity 'morbidity' named entity 'mucus' named entity 'H1N1' named entity 'COVID-19' named entity 'human health' named entity 'upper respiratory tract' named entity 'nasal spray' named entity 'RSV' named entity 'Ortervirales' named entity 'Hokkaido' named entity 'Monto' named entity 'lectin' named entity 'infectious disease' named entity 'seaweeds' named entity 'adenovirus' named entity 'griffithsin' named entity 'viral upper respiratory tract infection' named entity 'influenza' named entity 'antiviral' named entity 'polysaccharides' named entity 'human beings' named entity 'iota-carrageenan' named entity 'flu pandemic' named entity 'health problem' named entity 'respiratory infections' named entity 'Boehringer Ingelheim' named entity 'Emerging pathogens' named entity 'brown algae' named entity 'Ireland' named entity 'viral infections' named entity 'SARS-CoV-2' named entity 'COVID-19 infection' named entity 'I.P.' named entity 'SARS' named entity 'swine flu' named entity 'Hong Kong flu' named entity 'parainfluenza virus' named entity 'Coronaviridae' named entity 'coronavirus' named entity 'SARS-CoV' named entity 'viruses' named entity 'influenza virus' named entity 'coronavirus' named entity 'Monto' named entity 'fungi' named entity 'virus' named entity 'severe acute respiratory syndrome' named entity 'green algae' named entity 'red alga' named entity 'Asian flu' named entity 'April 2020' named entity 'robustum' named entity 'coronavirus' named entity 'infection' named entity 'influenza' named entity 'pandemics' named entity 'nasal spray' named entity 'respiratory syncytial virus' named entity 'virus' named entity 'human coronaviruses' named entity 'zanamivir' named entity 'viruses' named entity 'Nidovirales'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software